| Name | Title | Contact Details |
|---|
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.
Optogenics Of Syracuse Inc is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mindray North America is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We hold market leading positions in advanced wound care, ostomy care, continence and critical care and infusion devices. Our customers depend on our advanced technologies to help reduce potential complications of skin breakdown and infection, and they rely on our products and services to help manage their conditions every day. Meeting their needs is what motivates us and is a source of tremendous pride for our nearly 9,500 employees who are based in more than 110 countries worldwide. At ConvaTec, we exist to improve the lives of the people we touch. We are committed to helping people with chronic health conditions lead the life they want – giving them more mobility, confidence and freedom. Our vision is to be recognised as the most respected and successful MedTech company, worldwide. To achieve this, we drive for excellence in all that we do – anticipating and addressing our customers` needs with advanced technologies and best-in-class products and services. Our values-based culture helps drive our success. Caring for People: We are passionate about improving people`s lives and put people at the centre of everything we do. Driving Innovation and Excellence: We are dedicated to finding innovative solutions that anticipate and address our customers` needs and to delivering best-in-class execution. Earning Trust: We earn trust by delivering quality products and services that our customers can rely on. Our personal actions underpin this trust – we do what we say we will do.
Patrick Treacy, Antony Koblish and Adele Oliva saw a unique opportunity for one company to demonstrate leadership and set the agenda for innovation in surgical oncology. Founded in 2015, with best-in-class innovation partners, Onkos Surgical will deliver high quality implants and instruments that meet the unique needs of musculoskeletal tumor patients. From modular segmental systems to customized solutions and patient specific products, Onkos Surgical will partner with surgeons to provide new innovations to help address complex cases. Onkos Surgical has capabilities to increase the speed and delivery of innovation. Onkos Surgical is leveraging new technologies, such as 3D printing, to meet the unique needs of the cancer patient or surgeon. Onkos Surgical will develop products for both hard and soft-tissue applications while continuing to explore strategic partnerships to differentiate our product portfolio. With great customer responsiveness, manufacturing lead-times and quality, our vision is to be able to service and support the needs of the surgical oncologist.